BRAF inhibitor gives striking survival advantage in BRIM-3: Commentary

Oncology Report

Volumn , Issue JULY-AUGUST, 2011, Pages 29-

  Sosman, Jeffrey A ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DACARBAZINE; IPILIMUMAB; LACTATE DEHYDROGENASE; VEMURAFENIB;

CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; MELANOMA; NOTE;

EID: 80052286473     PISSN: 15485323     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (0)